All News

Primary care is where early detection and treatment of liver disease should begin and as Dr Alkhouri highlights here, all the right tools are already at hand.

The national study on the true prevalence of metabolic dysfunction-associated liver disease is essential to screening, prevention, and treatment efforts, says AFL CEO Stiehl.

Adults receiving semaglutide for the first time achieved weight loss of 14.3% at 12 months vs 10.6% among those who had previously taken a different antiobesity drug.

Your daily dose of the clinical news you may have missed.

Pivmecillinam is an aminopenicillin, a class of beta-lactam antibiotics with a mechanism of action that may help reduce rising levels of antibiotic resistance.

More participants consuming either of 2 common IBS dietary regimens experienced significant and sustained symptom relief vs those given pharmacotherapy.

Poor cardiovascular health at midlife was associated with a decline in the mental processing speed of Black women, but not White women, according to a new study.

Your daily dose of the clinical news you may have missed.

Alkhouri, a veteran investigator in the field of hepatic disease, including MASLD and MASH, stresses the need for early detection of MASLD when simple intervention can be effective.

Patients with AF aged younger than 65 years have substantial comorbidity burden that may impact their future risk of mortality, reported researchers.

Your daily dose of the clinical news you may have missed.

Treatment by female physicians resulted in better 30-day outcomes for male and female patients, but the benefit was significantly greater for the women.

Increased arterial stiffness and elevated central BP are among factors researchers found to have strong discriminatory value for PE at term and postpartum.

Researchers found that the COVID-19 booster dose elicited a 71%-84% increase in the median anti-spike half-life over that of the primary series.

Vedolizumab for subcutaneous injection in now indicated for maintenance therapy following IV induction in both Crohn disease and ulcerative colitis.

Your daily dose of the clinical news you may have missed.

Based on the classes' cardio- and renoprotective benefits, the ACP recommends SGLT2i and GLP1RA as second-line therapy in adults with T2D who are most likely to benefit.

The study that led to an historic expanded label for bempedoic acid must be followed by more like it, said Steven Nissen, MD. There is much more to do.